Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gliomas in people with NF1 show alterations in the RAS/MAPK pathway, generally in the absence of BRAF alterations (common to sporadic pilocytic astrocytomas) or IDH or histone H3 mutations (common to diffuse gliomas subsets).
|
30963251 |
2020 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No significant differences regarding additional imaging features emerged between BRAF V600E-mutant and wild-type lesions, with the exception of the number of tumors with cystic components, significantly higher in BRAF V600E-mutant PAs (p = 0.011) CONCLUSION: Assessment of the DWI characteristics of GGs and PAs may assist in predicting BRAF V600E status, suggesting a radiogenomic correlation and prompt molecular characterization of these tumors.
|
31667545 |
2020 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma.
|
31329636 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KIAA1549-BRAF is the most frequently identified genetic mutation in sporadic pilocytic astrocytoma (PA), creating a fusion BRAF (f-BRAF) protein with increased BRAF activity.
|
30504064 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
More recently, cases of PA with gangliocytic differentiation (PA-GD) have been described, and these cases are thus far restricted to those with the KIAA1549-BRAF fusion.
|
31147230 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The review of imaging features indicated that cyst formation is associated with the existence of KIAA1549-BRAF fusion in PA and GG and the lack of BRAF mutation in GG.
|
31147232 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results further emphasize the importance of BRAF alterations in PA and the need to characterize them in a given tumor as this can affect therapeutic strategies and their potential use as tumor marker in molecular diagnostics.
|
30575814 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pilocytic astrocytomas are grade 1 tumors usually occurring in children and young adults with KIAA1549-BRAF fusion defining the majority of pilocytic astrocytomas.
|
31355086 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We report actionable targets, including frequent FGFR1 mutation in optic-pathway PA that makes them excellent candidates to anti-FGFR therapies, and BRAF non-canonical mutations in PA.
|
31673897 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.
|
31087282 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Correlation between magnetic resonance imaging characteristics and BRAF alteration status in individuals with optic pathway/hypothalamic pilocytic astrocytomas.
|
31228537 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.
|
31321520 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pilocytic astrocytoma (PA), the most common childhood brain tumor, is a low-grade glioma with a single driver BRAF rearrangement.
|
31427603 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Correction: A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
|
28880959 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic mechanisms such as activation of MAPK, BRAF gene deregulation and neurofibromatosis type 1 (NF1) syndrome have been associated with PA development.
|
30570705 |
2019 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAF fusion involving the KIAA1549 gene is a hallmark of pilocytic astrocytoma, but it has also been recorded in rare cases of gangliogliomas, 1p/19q co-deleted oligodendroglial tumors, and it is also a common feature of disseminated oligodendroglial-like leptomeningeal neoplasm.
|
29802359 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma.
|
30265855 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Abnormalities in proto-oncogene B-Raf (BRAF) are typical in several subgroups of gliomas, including pilocytic astrocytomas, optic nerve gliomas, pleomorphic xanthoastrocytomas (PXA), anaplastic PXAs and gangliogliomas.
|
30013630 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mean score of BRAF expression in the PA group was significantly higher than that in the GS group (p = 0.019).
|
29168690 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, KIAA1549-BRAF fusion gene was identified by fluorescence in situ hybridization (FISH), supporting for the diagnosis of PA.
|
29768357 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These tumors expressed GFAP (5/6), OLIG2 (2/3), and S100 (1/1), and the pilocytic astrocytoma was negative for BRAF (V600E) mutant protein.
|
30074494 |
2018 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations are most frequently detected in certain subtypes of low-grade glioma, such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA), ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNT).
|
27792249 |
2017 |
Pilocytic Astrocytoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, 1p19q co-deletion and KIAA1549:BRAF fusion were, respectively, restricted to Oligodendroglioma and Pilocytic Astrocytoma.
|
26957305 |
2017 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The mitogen-activating protein kinase (MAPK) pathway and, more specifically, BRAF mutations have been shown to be prevalent in pediatric pilocytic astrocytomas and may represent one such area to target.
|
28009226 |
2017 |
Pilocytic Astrocytoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using a combined analysis of RNA sequencing and copy number variation data we identified a new BRAF fusion involving the 5' gene fusion partner GTF2I (7q11.23), not previously described in PA.
|
28448514 |
2017 |